B

Brainstorm Cell Therapeutics
D

BCLI

1.50000
USD
-0.14
(-8.54%)
Market Open
Volume
2,420
EPS
0
Div Yield
0
P/E
-7
Market Cap
125,979,864
Related Instruments
    I
    ICL
    -0.13000
    (-3.09%)
    4.08000 USD
News

Title: Brainstorm Cell Therapeutics

Sector: Healthcare
Industry: Biotechnology
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.